Bayer AG (OTC: BAYRY), Pan American Silver Corp (NASDAQ: PAAS), Motorola Mobility (NYSE: MMI), Vertex Pharmaceuticals (NASDAQ: VRTX), Office Depot, Inc. (NYSE: ODP) and Churchill Downs, Inc. (NASDAQ: CHDN) upgraded by analysts.
Motorola Mobility (MMI) was upgraded by JPMorgan Chase & Co. (NYSE:JPM) from an “Underweight” rating to a “Neutral” rating.
Vertex Pharmaceuticals (VRTX) was upgraded by William Blair from a “Market Perform” rating to an “Outperform” rating.
Pan American Silver Corp. (PAAS) was upgraded by Canaccord Genuity from a “Hold” rating to a “Buy” rating.
Bayer AG (BAYRY) was upgraded by Nomura from a “Neutral” rating to a “Buy” rating.
Office Depot, Inc. (ODP) was upgraded by UBS AG from a “Sell” rating to a “Neutral” rating. They have a price target of $3.00 on the company.
Churchill Downs, Inc. (CHDN) was upgraded by Hilliard Lyons from a “Neutral” rating to a “Buy” rating. They have a price target of $52.00 on the company.
Showing posts with label Bayer. Show all posts
Showing posts with label Bayer. Show all posts
Thursday, August 18, 2011
Wednesday, November 24, 2010
Regeneron Pharma's (NASDAQ:REGN) VEGF Trap-Eye Solution Works!
After two late-stage tests on Regeneron Pharma's (NASDAQ:REGN) and Bayer's VEGF Trap-Eye solution were successfully completed, the results were it worked as good as Roche’s ranibizumab (Lucentis), which they are sure to take market share away from when it hits the market.
Canaccord said, "Regeneron spiked early Monday after the drug developer and partner Bayer AG said their potential injectable treatment for the eye disease wet age-related macular degeneration worked as well as Roche’s ranibizumab (Lucentis) in two late-stage studies. The companies are developing the VEGF Trap-Eye solution as a treatment for the disease, which results in vision loss as new blood vessels grow beneath the retina and leak blood and fluid, damaging the retina and distorting vision. The condition, which can progress to blindness, usually affects older adults. Analysts at Brean Murray note that giving VEGF Trap Eye every two months was at least as good as monthly 0.5 mg ranibizumab, which halves the number of undesirable intraocular injections. Patient vision generally suffers as one tries to minimize their number of eye injections by seeking therapy only when they deem their visual acuity to be low. Therefore, a less frequent therapy that is at least as effective as ranibizumab is
extremely desirable and should garner significant market share."
Regeneron closed Tuesday at $29.99, rising by $0.46, or 1.56 percent.
Canaccord said, "Regeneron spiked early Monday after the drug developer and partner Bayer AG said their potential injectable treatment for the eye disease wet age-related macular degeneration worked as well as Roche’s ranibizumab (Lucentis) in two late-stage studies. The companies are developing the VEGF Trap-Eye solution as a treatment for the disease, which results in vision loss as new blood vessels grow beneath the retina and leak blood and fluid, damaging the retina and distorting vision. The condition, which can progress to blindness, usually affects older adults. Analysts at Brean Murray note that giving VEGF Trap Eye every two months was at least as good as monthly 0.5 mg ranibizumab, which halves the number of undesirable intraocular injections. Patient vision generally suffers as one tries to minimize their number of eye injections by seeking therapy only when they deem their visual acuity to be low. Therefore, a less frequent therapy that is at least as effective as ranibizumab is
extremely desirable and should garner significant market share."
Regeneron closed Tuesday at $29.99, rising by $0.46, or 1.56 percent.
Subscribe to:
Posts (Atom)